長期滞在時間を持つリシン標的可逆共性阻害剤
Rahi M Reja1, Wenjian Wang1, Yuhan Lyu1
1Department of Chemistry, Boston College, 2609 Beacon Street, Chestnut Hill, Massachusetts 02467, United States.
Journal of the American Chemical Society
|January 18, 2022
まとめ
研究者は新しいダイアザボリンを用いた新しい可逆性ライシン結合を開発し,長時間作用する可逆性共性阻害剤を作成しました. このアプローチは解離を著しく遅らせ,ソルターゼ抑制のための以前のイミノボロナート化学を上回る.
科学分野:
- 薬剤化学
- 生物化学
- 化学生物学
背景:
- リバーシブル共性阻害剤は,持続的な標的の関与を提供することで,従来の薬よりも利点があります.
- 既存のイミノボロナート化学は,可逆的な共性抑制を可能にしますが,急速な解離運動に苦しむことがあります.
- スタフィロコクスのソルターゼは,抗菌剤開発の有効な標的であり,細菌の毒性にとって極めて重要です.
研究 の 目的:
- リバーシブルライシン結合のための新しいダイアザボリン形成弾頭 (RMR1) を導入する.
- スタフィロコクスのソルターゼに対する長期作用の可逆共性阻害剤の成分としてRMR1の有効性を評価する.
- 既存のイミノボロナート化学と新しいディアザボリン化学の解離運動を比較する.
主な方法:
- 新型ダイザボリン形成弾頭RMR1の合成と特徴付け
- スタフィロコックスのソルターゼを標的とするペプチドリガンドへのRMR1の結合.
- 生物化学的および細胞ベースの測定法により,ソルターゼ抑制と化合物の有効性を評価する.
- イミノボロナートベースの阻害剤とRMR1ベースの阻害剤の比喩的運動研究
主要な成果:
- 新しいダイアザボリン剤は,イミノボロナートと比較して,解離運動を著しく遅らせます.
- RMR1結合ペプチドリガンドは,スタフィロコックスのソルターゼを強力に長期間抑制することが示されています.
- 効果は in vitro 生化学的測定と細胞ベースの実験の両方で確認されました.
結論:
- ダイアザボリン形成型核弾頭RMR1は,可逆共性阻害剤の設計における重要な進歩を表しています.
- 結合解離運動を調節することは,効果的な長期作用の可逆共性阻害剤を開発するための重要な戦略です.
- この新しい化学反応は 細菌ソルターゼや他の酵素を標的とした 新種の治療薬の開発に 期待されています
関連する概念動画
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.1K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.1K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
700
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
700
01:30Enzyme Inhibition
81.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
81.7K
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
1.2K
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.2K
00:49Ligand Binding and Linkage
5.0K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.0K
02:40Ligand Binding Sites
14.0K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
14.0K